Authors
Loading...
Study reveals anti-PLP antibodies drive inflammation and demyelination in multiple sclerosis, indicating a potential target for therapy.
Tobias V Lanz (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: